Resection of “down-staged” advanced hepatocellular carcinoma after treatment with the VEGFR2 inhibitor apatinib: five cases report

Sorafenib and lenvatinib are currently standard treatments for advanced hepatocellular carcinoma (HCC); however, the therapeutic effect is unsatisfying. Indeed, very few patients with HCC under sorafenib treatment were eligible for surgery in the past ten years. In addition, there is no report of a...

Descripción completa

Detalles Bibliográficos
Autores principales: Hou, Zhenyu, Zhu, Keyun, Yang, Xuejiao, Zhou, Hongyuan, Chen, Ping, Yu, Ge, Zhu, Xiaolin, Cui, Yunlong, Song, Tianqiang, Li, Qiang, Li, Huikai, Zhang, Ti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799223/
https://www.ncbi.nlm.nih.gov/pubmed/35117862
http://dx.doi.org/10.21037/tcr-19-3019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799223/
https://www.ncbi.nlm.nih.gov/pubmed/35117862
http://dx.doi.org/10.21037/tcr-19-3019

Ejemplares similares